[{"id":"190221a9-bff3-43f0-a9e5-28701dc39793","acronym":"","url":"https://clinicaltrials.gov/study/NCT05651100","created_at":"2022-12-14T14:58:24.658Z","updated_at":"2024-07-02T16:35:59.162Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma","source_id_and_acronym":"NCT05651100","lead_sponsor":"Kecellitics Biotech Company Ltd","biomarkers":" CD22","pipe":" | ","alterations":" CD19 expression • CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression • CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CD19/CD22 chimeric antigen receptor T cell"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 12/10/2022","start_date":" 12/10/2022","primary_txt":" Primary completion: 12/10/2024","primary_completion_date":" 12/10/2024","study_txt":" Completion: 12/10/2025","study_completion_date":" 12/10/2025","last_update_posted":"2022-12-14"}]